We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00266357
First Posted: December 16, 2005
Last Update Posted: January 14, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
H. Lundbeck A/S
December 14, 2005
December 16, 2005
January 14, 2015
November 2005
March 2007   (Final data collection date for primary outcome measure)
Mean of total sleep time over 2 nights.
Same as current
Complete list of historical versions of study NCT00266357 on ClinicalTrials.gov Archive Site
Mean of other PSG sleep parameters over 2 nights, mean of subjective sleep parameters, and exploratory residual effect.
Mean of other PSG sleep parameters over 2 nights, mean of subjective sleep parameters, and exploratory redidual effect.
Not Provided
Not Provided
 
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
MK0928 Phase II Sleep Laboratory Study - Primary Insomnia
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Primary Insomnia
  • Drug: MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)
  • Drug: Placebo / Duration of Treatment: 2 days for screening period
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
50
Not Provided
March 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with a diagnosis of primary insomnia

Exclusion Criteria:

  • Patients with an active psychiatric disorder other than primary insomnia
Sexes Eligible for Study: All
20 Years to 64 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Japan
 
NCT00266357
0928-041
2005_107
Not Provided
Not Provided
Not Provided
Not Provided
H. Lundbeck A/S
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
H. Lundbeck A/S
January 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP